We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Should Athletes Be Screened for Sickle Cell Trait?

By LabMedica International staff writers
Posted on 21 Sep 2010
An extensive and high-profile screening program to test college athletes in the United States for the sickle cell anemia gene has evoked some controversy. More...


Starting this academic year, the [U.S.] National Collegiate Athletic Association (NCAA) plans to screen close to 167,000 college athletes for sickle cell trait. Students participating in athletics at Division I schools will be tested for the gene responsible for sickle cell disease. The program aims to identify carriers of a single sickle-cell gene--not those who carry two such genes, and have sickle-cell disease.

Those who inherit sickle-cell genes from both parents will have sickle-cell anemia, a chronic and painful disease in which red blood cells fail to carry oxygen efficiently to muscles and organs. However, those who carry a single gene have no outward symptoms of the genetic affliction, which mostly affects those of African descent.

Carriers of the sickle-cell gene are more prone than those without the gene to develop a potentially deadly muscle-wasting condition called rhabdomyolisis after intense physical exertion, as well blockages in blood vessels carrying oxygen to the spleen (especially when exercising at high altitudes).

The proposed [U.S.] National Collegiate Athletic Association (NCAA) screening is expected to identify 400 to 500 carriers each year. Eight percent of African-Americans carry at least a single sickle-cell gene (rates among Latinos and white Americans are .08% and .02% respectively).

In a commentary published in the September 9, 2010, New England Journal of Medicine (NEJM), attorney Vence L. Bonham and scientist Lawrence C. Brody of the [U.S.] National Human Genome Research Institute (NHGRI; Bethesda, MD, USA), and Johns Hopkins Children's Center (Baltimore, MD, USA) pediatrician George Dover noted that the NCAA has failed to put in place measures that protect athletes identified as carriers from stigma or discrimination. Nor have they arranged counseling on what their status means (and does not mean), and how they might protect themselves from the risks that come with it. They warned that the sickle cell testing "may also open the door to additional testing."

The commentary adds that because the tests will take place outside of a patient-physician relationship, athletes will lack confidentiality. The authors noted that for students on athletic scholarships, such testing could be viewed as coercive. In addition, they questioned why the program appears limited only to Division I schools. "Are athletes in NCAA Divisions II and III at less risk, and if not, why are they exempt from testing?"

However, the NCAA fact sheet about sickle cell trait testing states that athletes with sickle cell trait should not be excluded from participation as precautions can be put into place. Most U.S. states test at birth, but most athletes with sickle cell trait do not know they have it.

The NCAA recommends that athletics departments confirm the sickle cell trait status in all student-athletes. Knowledge of sickle cell trait status can be a gateway to education and simple precautions that may prevent collapse among athletes with the trait, allowing them to succeed in their sport.

A growing number of tests--medical and genetic--are becoming available to identify persons at particular risk of disease or injury. As employers and league officials embrace those tests to protect themselves and their members, they may look to the NCAA's new initiative.

Related Links:

[U.S.] National Collegiate Athletic Association
[U.S.] National Human Genome Research Institute
Johns Hopkins Children's Center




Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Capillary Blood Collection Tube
IMPROMINI M3
Silver Member
PCR Plates
Diamond Shell PCR Plates
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: MG Tech adds STOMmics Stereo-seq spatial multi-omics technology to its potfolio (photo courtesy of STOmics)

MGI Tech Strengthens Sequencing Portfolio with Dual Acquisition

MGI Tech Co., Ltd. (Shenzhen, China) announced the acquisition of STOmics and CycloneSEQ on March 3, 2026, as part of its “SEQALL+GLI+Omics” strategy. According to the company, the combined portfolio spans... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.